CRISPR Epigenetic Therapeutics for Pain Management
Search text
About 24 results
(0.07 seconds)
Researchers at Pitt have developed a pain-enabled in vitro system to study pain mechanisms and develop treatments specifically related to osteoarthritis (OA) and its associated pain. Researchers at Pitt have developed a pain-enabled in vitro system to study pain mechanisms and develop treatments specifically related to osteoarthritis (OA) and its associated pain. OA is a condition characterized by joint damage, leading to pain and disability, and the primary therapeutic target is to address the resulting pain.
The CRISPR/Cas9 gene editing system has emerged as an exciting new tool for a wide range of applications, including customized genetic engineering, gene therapy, and treating viral infections. The FDA has approved CRISPR/Cas9 for use in human clinical trials, and several companies are working toward commercialization. To make CRISPR/Cas9 safer and more effective, we modified the system to be light-activated so that users can unleash this powerful gene editing tool precisely when and where it is needed.
- Treatment of persistent pain (inflammatory and neuropathic pain). University of Pittsburgh researchers have developed a novel gene therapy targeting specific subsets of neurons involved in persistent pain, including inflammatory and neuropathic pain. - Research in neural signaling and pain pathways.